China, Nine Other Nations Represented At U.S. FDA Heparin Talks
This article was originally published in PharmAsia News
China regulators joined counterparts from nine other countries at U.S.-hosted meetings to discuss the status of the blood-thinner heparin. Contaminated supplies of heparin were traced to China after 62 deaths were reported among patients who had been given the heparin drug. Details of the discussions were not revealed in advance of an April 21 meeting orchestrated by the U.S. FDA, which hosted the two days of meetings with the representatives. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.